

<b>BSE SENSEX</b>	<b>S&amp;P CNX</b>
74,333	22,553

**CMP: INR1166**

**Rating: NA**

## Stock Info

Bloomberg	SUVENPHA IN
Equity Shares (m)	25
M.Cap.(INRb)/(USD\$b)	299 / 3.4
52-Week Range (INR)	1360 /597
1, 6, 12 Rel. Per (%)	NA
12M Avg Val (INR M)	NA
Free float (%)	49.9

## Proforma Financials Snapshot (INR b)

Y/E March	FY22	FY23	FY24
Sales	26.0	26.8	23.9
EBITDA	9.6	10.1	7.8
Adjusted PAT	5.8	6.7	4.9
PAT Growth (%)	14.5	16.4	-26.9

## Ratios

RoE (%)	26.0	26.1	21.1
RoCE (%)	49.0	42.6	30.8

## Shareholding Pattern (%)

As On	Dec-24	Sept-24	Dec-23
Promoter	50.1	50.1	60.0
DII	10.8	10.7	10.1
FII	16.7	17.0	15.9
Others	22.4	22.3	13.9

## Building niche capabilities/capacities to boost CDMO offerings

We recently met with the management of Suven Pharma (SUVEN) to gain a deeper understanding of its business outlook.

- Suven is actively expanding its niche technologies in new modalities within the CDMO space through both organic and inorganic growth.
- After acquiring a majority stake in SUVEN in Sep'23, Advent International has re-strategized the company's growth drivers across the CDMO, API, and specialty chemicals segments.
- SUVEN has enhanced its R&D capabilities and strengthen its commercial presence in developed markets (US/EU/Japan). The company offers niche offerings in Anti-body Drug Conjugates (ADCs), oligonucleotide, and small molecules.
- SUVEN has established the necessary building blocks to achieve its USD1b revenue target, up from the revenue of USD318m in 9MFY25 (proforma basis). We believe successful execution will be crucial to achieving this target.

## Key highlights from the management meet

### ADCs – Strong value chain presence and growing interest from innovators position SUVEN favorably

- The ADC segment has clocked the highest CAGR of 20% in R&D spending over FY19-24, led by a focus on targeted therapies to improve efficacy and reduce side effects.
- SUVEN has positioned itself to support innovator pharma companies across the entire journey, from drug discovery to commercialization.
- The ADC outsourcing CDMO industry is expected to achieve a 23% CAGR over the next five years, reaching a market size of USD4b.
- Given the complex nature of the products, only 13 ADCs have been approved in the US to date, while almost 75 ADC projects have been discontinued.
- The total value of approved ADC products to date is approximately USD11b, with the two Topoisomerase I inhibitor-based products contributing over 40%.
- Suven/Cohance are the exclusive suppliers of the CPT-based payload supply chain, leveraging USFDA-approved, contained facilities with best-in-class purity and stability.
- That said, there has been a resurgence in ADC clinical trial projects (~270), led by the success of products like Enhertu/Trodely, which have shown a 37%/59% reduction in the risk of disease progression or death for patients with breast cancer.
- The development of a successful ADC candidate requires the proper integration of the receptor (target), antibody, linker, and payload. Challenges in any of these components can lead to clinical failure and the withdrawal of the drug program.
- Interestingly, ADCs that deliver Topoisomerase I inhibitors have witnessed a discontinuation rate of less than 5%.

**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Research Analyst - Akash Manish Dobhada** (Akash.Dobhada@MotilalOswal.com) | **Viraj Shah** (Viraj.Shah@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- There are about 104 clinically active compounds based on S-trione. Notably, it is one of the key products supplied by SUVEN/Cohance.
- With its library of payload linkers, capacity expansion in India/US, and diverse payload capabilities, SUVEN, in partnership with NJ Bio, is considerably expanding its scope of business in the ADC outsourcing segment (7x expansion in market coverage to USD1.4b in CY24).

#### **Oligonucleotide – Another growth lever in the CDMO segment**

- The oligonucleotide outsourcing CDMO industry is expected to achieve a 25% CAGR, reaching USD4b by FY29. Nucleic acids & oligos are vital for R&D in therapeutics, diagnostics, and synthetic biology.
- The amidite and GalNAc segments are expected to grow at a faster rate than the overall oligonucleotide market.
- With SUVEN's a) capability to synthesize a spectrum of modified amidites and nucleosides, and b) efforts to expand its capacity, the company is adding a niche offering to its CDMO segment.

#### **Small molecules – Expanding customer base; new RFQs from select biotech companies**

- About 52% of the total R&D pipeline in the clinically active phase is in the small molecules segment. As a result, the share of small molecules in approved novel drugs remains high at 68%.
- SUVEN has 100+ projects across Phase I/II of R&D. The number of intermediate projects in the Phase III clinical stage has increased from 6 to 15 (i.e. 2 molecules to 9 molecules).
- Interestingly, RFQs have doubled YoY.
- SUVEN is focused not only on securing more business from existing customers but also attracting new customers and advancing its position within the value chain.

#### **API/spec-chem – New introduction and demand recovery to aid growth**

- SUVEN has increased the number of product validations over the past 18-24M. It aims to add seven+ products to the API segment in FY25.
- A strong sequential recovery and increased RFQs are expected to drive business growth in the innovator-focused agricultural chemicals segment. The company is working towards adding new customers and moving up the value chain in the agriculture CDMO business as it has converted this segment into a strategic business unit.

#### **Other key highlights**

- The SUVEN-Cohance merger is on track and is expected to be completed by 1QFY26.

## Well-placed in the high-growth CDMO space

- SUVEN generates 53% of its revenue from CDMO services (small molecules, ADCs, and oligonucleotides).
- It offers end-to-end CRDMO capabilities in the ADC segment, spanning from pre-clinical trials to commercial manufacturing. It currently supplies two ADCs commercially and holds a leadership position in S-Trione.
- Through its acquisition of NJ Bio, SUVEN has gained access to an extensive payload library, along with niche capabilities in linker & P/L synthesis and bio-conjugation.
- SUVEN specializes in oligonucleotide and mRNA building blocks, including GalNAc and Tricyclo-DNA, with global exclusivity, strong backward integration, and a growing presence through forward integration and cGMP investments.
- SUVEN has a robust small molecule presence, with 14 of the top 20 innovators driving 80% of revenue. The company also has a robust pipeline of 100+ molecules, with growing demand evidenced by a 2x YoY increase in RFQ inflows.

## Presence across the small molecules value chain places SUVEN uniquely among peers

- SUVEN has a presence across specialized as well as standardized small molecules, with the exception of fermentation capabilities.
- It has a strong presence across HPAPI, ADC, Protein Degraders, and oligonucleotides. The TAM of SUVEN’s high-growth technology platforms, including ADC, oligonucleotide, and protein degraders, is valued at USD4.3b.

**Exhibit 1: SUVEN has strong presence across specialized technologies in small molecules**

Specialized Technologies – Small Molecules	Suven+Cohance	EU Peer 1	EU Peer 2	Chinese Peers
HPAPI – Cytotoxic Drugs	★★★	★★★		★★
Controlled Substance	★★			
Flow Chemistry	★	★★★		★★
Antibody-Drug Conjugates	★★★	★★★		★★★
PROTACs (Protein Degraders)	★★★			★★★
Oligonucleotides and Amidites	★★	★★★	★★★	★★★
Peptides	★		★★★	★★★
Fermentation		★★★		★★★
<b>Standard Small Molecules</b>				
Discovery	★			★★★
Development	★★	★★		★★★
Manufacturing	★★	★★		★★★
<b>Biologics/Large Molecules</b>				
Monoclonal Antibodies and Recombinant Technology		★★		★★★
Cell and Gene Therapy		★★		★★★
	★★★	Very Strong		
	★★	Strong		
	★	Emerging/less established Capability		
		N/A		

Source: MOFSL, Company

- Among high-growth technologies, including HPAPI, ADC, PROTACs, oligonucleotides, and peptides, SUVEN competes with several standalone players in niche technologies globally, especially in the EU and China. However, there may not be a direct competitor with the same combined capabilities.
- That said, SUVEN is building its expertise across the value chain through both organic and inorganic investments.

### **SUVEN is well-placed in the high-growth ADC market with end-to-end capabilities**

- SUVEN offers end-to-end CRDMO capacity and capabilities in the ADC space, covering 75% of the payload market. The company provides a range of services, spanning from pre-clinical trials to end manufacturing.
- Prior to the acquisition of NJ Bio, SUVEN was engaged in clinical phase trials and commercial manufacturing.
- Following the acquisition, SUVEN gained access to an extensive library of 500+ payload linkers and expanded its presence across the ADC value chain, from pre-clinical trials to commercial manufacturing.
- Additionally, SUVEN acquired capabilities in linker & P/L synthesis and bio-conjugation through NJ Bio.
- It offers integrated services for standard and custom payload linkers, along with analytical services and bio-conjugation.
- The company is supplying two ADCs commercially and holds a leadership position in S-Trione, a key intermediate in camptothecin derivatives.

### **Entering the emerging and high-growth oligonucleotides market**

- SUVEN is amongst the few CDMOs globally specializing in the oligonucleotide and mRNA building blocks, including GalNAc and Tricyclo-DNA, for which the company is the sole supplier in the world.
- The company is capable of synthesizing a spectrum of modified amidites and nucleosides with high purity levels, supported by backward integration for over 15 steps.
- It has a diversified innovator customer base, with a strong presence in Japan. It also offers multi-kilo scale synthesis of a wide variety of GalNAc compounds, providing innovators with the highest purity profile.
- To further enhance growth, SUVEN is forward integrating by investing in a cGMP facility and driving R&D growth in the segment.

### **Presence across the innovator value chain to drive growth in the small molecule space**

- SUVEN has a strong presence in small molecule, with 14 out of 20 top innovator companies contributing over 80% of the revenue.
- It has more than 100 molecules under development, spanning across phase 1 to phase 3 of clinical trials. It has commercialized 16 molecules that are patented across platforms.
- To further strengthen its pipeline, it has 9 molecules and 15 intermediates under phase 3 clinical trials.
- Over 9MFY25, the company witnessed a 2x YoY increase in RFQ inflows from new customers and category expansion.


## Growing outsourcing landscape in the ADC-CDMO segment

- ADCs represent an innovative class of chemotherapeutics targeted towards cancer therapy, offering high efficacy.
- Considering the geopolitical scenario and the need for supply chain de-risking from Chinese players, the company is strengthening its expertise through organic as well as inorganic means.
- Due to the complex manufacturing process, only 13 drugs have been approved by the FDA to date, while ~270 drugs are in the clinical stage and 77 drugs have been discontinued.
- With the acquisition of NJ Bio, SUVEN is uniquely placed in the entire value chain of the ADC market, with a vast library of payload linkers, a presence spanning drug discovery to manufacturing, and plans for capacity expansion.

### SUVEN strengthening its global presence across complex ADC value chain

- ADCs represent an innovative class of chemotherapeutics, which combines the precision of monoclonal antibodies (mAbs) with potent cytotoxic agents.
- Each generation of ADCs has steadily progressed toward the goal of targeted cancer therapy, with enhanced efficacy and reduced off-target toxicity.
- Notably, there have been 13 USFDA approvals to date, with over 1,700 ADCs currently in various stages of development.
- The momentum in this field is underscored by several billion-dollar industry deals, with global sales exceeding USD9b in CY23.


**Exhibit 2: Evolution of ADC from inception to innovation**



Source: MOFSL, Company

- Developing a successful ADC candidate requires the proper integration of the receptor (target), antibody, linker, and payload. Challenges in any of these components can lead to clinical failure and withdrawal of the drug program.
- As of Jan'25, 77 ADC projects have been discontinued and several other projects are currently inactive, highlighting the inherent complexities and difficulties involved in matching the linker payload and mAb specifically to the target.


**Exhibit 3: Anatomy of an ADC**



Source: MOFSL, Company

**Exhibit 4: Development status of 416 ADC-related projects**

■ Approved ■ Clinically active ■ Discontinued




Source: MOFSL, Company

- The ADC approach enhances specificity, thereby increasing therapeutic efficacy, minimizing toxicity, and reducing the required dosage.
- Having said this, the ADC market is expected to clock 31% CAGR over CY24-30 to reach USD66b.

**Exhibit 5: ADC market is expected to clock 31% CAGR to USD66b by CY30**


■ Global ADC Market (USDb)



Source: MOFSL, Wuxi XDC


- The ADC CDMO market is expected to clock 25%+ CAGR over CY24-29, reaching USD4b, driven by increased investment in R&D for the development of drugs.
- Over CY19-24, ADC has witnessed a 20% rise in the R&D pipeline, led by the complex nature and high efficacy of the drug delivery system.
- Currently, ~270 molecules are in various stages of clinical development.

**Exhibit 6: ADC CDMO market to reach USD4b by CY29**



Source: MOFSL, Company

**Exhibit 7: By CY29, 1328 molecules to be under clinical development**



Source: MOFSL, Company

- With the acquisition of NJ Bio, SUVEN has not only enhanced its manufacturing capabilities in linker & PL synthesis but also gained bio-conjugation capabilities.
- Further, the acquisition has allowed SUVEN to unlock its discovery and pre-clinical capabilities, leveraging a vast library of payload linkers from NJ Bio, which covers 75% of the payload market.
- This positions SUVEN uniquely to gain market share globally in the ADC market.
- Additionally, the company is expanding its capacity in the US and India while broadening its portfolio by adding new payloads and linkers, which will drive significant growth.

**Exhibit 8: NJ Bio unlocks new capabilities within the ADC manufacturing process**

	Monoclonal Antibody	Payload	Linker & P/L synthesis	Bio-conjugation	Fill-Finish
Suven Platform	✗	✓ ✓	✗	✗	✗
NJ Bio	✗	✓ ✓ ✓	✓ ✓ ✓	✓ ✓ ✓	✗
Combined	✗	✓ ✓ ✓	✓ ✓ ✓	✓ ✓ ✓	✗

Source: MOFSL, Company



## Turnaround/competitive edge to improve growth prospects in specialty chemicals/API++

- SUVEN's Specialty Chemicals segment (10% of total sales) has a presence across AgChem, Cosmetics, Electronic Chemicals, and Photochromic Lens.
- The company is focused on driving growth and profitability in this segment through a dedicated facility, a focused approach, and cost optimization strategies.
- API++ is Cohance's vertically integrated merchant API and pellet business, which targets low to mid API volumes with lower competition.
- Given the competitive edge of low-cost manufacturing, Cohance ranks among the top three globally in the top eight molecules. Additionally, the company has a strong pipeline that is expected to further boost future growth prospects.

## Turnaround of specialty chemicals business to improve growth/profitability over the medium term

- SUVEN has a strong presence in specialty chemicals, serving innovators in AgChem, Cosmetics, Electronic Chemicals, and Photochromic Lens.
- The specialty chemicals segment accounts for 10% of the company's sales.
- The company operates a dedicated facility in Vizag, with the potential for further capacity expansion in the future.
- The company has restructured its specialty chemical service line into a new strategic business unit, placing a greater focus on meeting customer expectations and business needs.
- SUVEN has started investing in domain experts, including operating partners, and is moving towards dedicated facilities and initiatives aimed at driving continuous improvements, such as automation and adherence to EHS best practices.
- Additionally, to improve margins, the company has started implementing cost-saving initiatives across its operations.

## Competitive edge in API++ to strengthen SUVEN's position in the global market post-merger

- API++ refers to Cohance's merchant API and pellet business, focusing on low to mid-volume APIs with lower competitive intensity.
- The company offers end-to-end vertically integrated solutions, including pellets and formulations.
- Cohance has maintained its competitive edge through backward integration, establishing a strong cost position.
- The company ranks among the top three global players in market share across most of the top 8 out of 10 molecules, demonstrating its leadership position in the industry.
- To further boost its growth prospects, the company has several new products in the pipeline.



## Proforma P&L - Suven + Cohance combined

Y/E March	FY20	FY21	FY22	FY23	FY24	9MFY24	9MFY25
<b>Revenue</b>	<b>16,969</b>	<b>20,140</b>	<b>26,004</b>	<b>26,779</b>	<b>23,922</b>	<b>16,903</b>	<b>17,691</b>
<i>YoY growth %</i>		<i>18.7</i>	<i>29.1</i>	<i>3.0</i>	<i>-10.7</i>	<i>-29.3</i>	<i>4.7</i>
COGS	5,997	7,024	9,291	9,283	8,006	5,667	5,279
<b>Gross Profit</b>	<b>10,972</b>	<b>13,116</b>	<b>16,713</b>	<b>17,496</b>	<b>15,916</b>	<b>11,236</b>	<b>12,412</b>
<i>Gross Margin %</i>	<i>64.7</i>	<i>65.1</i>	<i>64.3</i>	<i>65.3</i>	<i>66.5</i>	<i>67.5</i>	<i>70.2</i>
Manufacturing expenses	1,994	2,461	3,009	3,242	2,506	1,980	1,847
<i>Manufacturing expenses as a % of sales</i>	<i>11.8</i>	<i>12.2</i>	<i>11.6</i>	<i>12.1</i>	<i>10.5</i>	<i>11.9</i>	<i>10.4</i>
Employee Cost	1,924	2,195	2,719	3,038	3,771	2,779	3,310
<i>Employee Cost as a % of sales</i>	<i>11.3</i>	<i>10.9</i>	<i>10.5</i>	<i>11.3</i>	<i>15.8</i>	<i>14.1</i>	<i>18.7</i>
Other expenses	1,197	1,266	1,559	1,541	1,959	1,189	1,552
<i>Other expenses as a % of sales</i>	<i>7.1</i>	<i>6.3</i>	<i>6.0</i>	<i>5.8</i>	<i>8.2</i>	<i>6.9</i>	<i>8.8</i>
<b>EBITDA (pre Forex impact)</b>	<b>5,857</b>	<b>7,194</b>	<b>9,426</b>	<b>9,675</b>	<b>7,680</b>	<b>5,288</b>	<b>5,703</b>
<i>YoY growth %</i>		<i>22.8</i>	<i>31.0</i>	<i>2.6</i>	<i>-20.6</i>	<i>-23.7</i>	<i>-2.6</i>
<i>EBITDA margin %</i>	<i>34.5</i>	<i>35.7</i>	<i>36.2</i>	<i>36.1</i>	<i>32.1</i>	<i>34.7</i>	<i>32.2</i>
Forex gain/(loss)	224	261	208	415	102	98	118
Extra ordinary expense					752	594	329
<b>EBITDA (post Forex impact)</b>	<b>6,081</b>	<b>7,455</b>	<b>9,634</b>	<b>10,090</b>	<b>8,534</b>	<b>5,979</b>	<b>6,149</b>
<i>YoY growth %</i>		<i>22.6</i>	<i>29.2</i>	<i>4.7</i>	<i>-22.9</i>	<i>-23.7</i>	<i>-2.0</i>
<i>EBITDA margin %</i>	<i>35.8</i>	<i>37.0</i>	<i>37.0</i>	<i>37.7</i>	<i>32.5</i>	<i>35.1</i>	<i>32.9</i>
Depreciation	679	786	900	1,002	1,139	843	1,044
Finance cost	396	137	173	283	406	253	306
Other income	335	216	309	349	731	577	430
<b>PBT after extra ordinary expenses</b>	<b>5,341</b>	<b>6,748</b>	<b>8,870</b>	<b>9,154</b>	<b>7,720</b>	<b>5,420</b>	<b>5,529</b>
Tax	1,322	1,710	2,961	2,381	1,981	1,401	1,251
<i>Effective tax rate %</i>	<i>24.8</i>	<i>25.3</i>	<i>33.4</i>	<i>26.0</i>	<i>28.4</i>	<i>25.8</i>	<i>25.5</i>
<b>Reported PAT</b>	<b>4,018</b>	<b>5,038</b>	<b>5,910</b>	<b>6,773</b>	<b>5,739</b>	<b>4,019</b>	<b>3,978</b>
<i>YoY growth %</i>	<i>23.7</i>	<i>25.0</i>	<i>22.7</i>	<i>25.3</i>	<i>24.0</i>	<i>23.8</i>	<i>22.5</i>
<i>PAT margin %</i>	<i>23.7</i>	<i>25.0</i>	<i>22.7</i>	<i>25.3</i>	<i>20.8</i>	<i>23.8</i>	<i>20.6</i>

## Financials and valuations

### Consolidated - Income Statement- INR Millions

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24
<b>Total Income from Operations</b>	<b>3,778</b>	<b>8,338</b>	<b>10,097</b>	<b>13,202</b>	<b>13,403</b>	<b>10,514</b>
Change (%)	NA	120.7	21.1	30.8	1.5	-21.6
Raw Materials	1,032	2,292	3,019	3,991	4,091	3,150
Employees Cost	296	651	762	1,005	1,182	1,339
Other Expenses	735	1,548	1,886	2,389	2,388	1,946
<b>Total Expenditure</b>	<b>2,063</b>	<b>4,491</b>	<b>5,667</b>	<b>7,385</b>	<b>7,662</b>	<b>6,435</b>
% of Sales	54.6	53.9	56.1	55.9	57.2	61.2
<b>EBITDA</b>	<b>1,715</b>	<b>3,847</b>	<b>4,430</b>	<b>5,817</b>	<b>5,742</b>	<b>4,078</b>
Margin (%)	45.4	46.1	43.9	44.1	42.8	38.8
Depreciation	115	235	316	391	480	546
<b>EBIT</b>	<b>1,600</b>	<b>3,612</b>	<b>4,114</b>	<b>5,426</b>	<b>5,262</b>	<b>3,532</b>
Int. and Finance Charges	28	231	117	85	128	75
Other Income	6	663	680	1,335	464	619
<b>PBT bef. EO Exp.</b>	<b>1,578</b>	<b>4,045</b>	<b>4,677</b>	<b>6,676</b>	<b>5,598</b>	<b>4,077</b>
EO Items	-2	-77	-41	-980	0	-20
<b>PBT after EO Exp.</b>	<b>1,576</b>	<b>3,968</b>	<b>4,636</b>	<b>5,696</b>	<b>5,598</b>	<b>4,057</b>
Total Tax	486	875	1,053	2,138	1,484	1,054
Tax Rate (%)	30.8	22.1	22.7	37.5	26.5	26.0
Minority Interest	0	0	0	0	0	0
<b>Reported PAT</b>	<b>1,090</b>	<b>3,093</b>	<b>3,582</b>	<b>3,559</b>	<b>4,113</b>	<b>3,003</b>
<b>Adjusted PAT</b>	<b>1,092</b>	<b>3,153</b>	<b>3,614</b>	<b>4,171</b>	<b>4,113</b>	<b>3,018</b>
Change (%)	NA	188.8	14.6	15.4	-1.4	-26.6
Margin (%)	28.9	37.8	35.8	31.6	30.7	28.7

### Consolidated - Balance Sheet

(INR Million)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24
Equity Share Capital	127	127	255	255	255	255
Total Reserves	5,776	8,320	11,553	15,017	17,097	20,252
<b>Net Worth</b>	<b>5,903</b>	<b>8,448</b>	<b>11,808</b>	<b>15,272</b>	<b>17,352</b>	<b>20,507</b>
Minority Interest	0	0	0	0	0	0
Total Loans	828	1,862	1,430	971	703	650
Deferred Tax Liabilities	292	276	309	543	582	648
<b>Capital Employed</b>	<b>7,023</b>	<b>10,586</b>	<b>13,548</b>	<b>16,786</b>	<b>18,638</b>	<b>21,805</b>
Gross Block	3,474	4,568	5,688	6,950	8,153	8,641
Less: Accum. Deprn.	765	1,001	1,276	1,608	2,088	2,633
<b>Net Fixed Assets</b>	<b>2,709</b>	<b>3,567</b>	<b>4,412</b>	<b>5,342</b>	<b>6,066</b>	<b>6,007</b>
Goodwill on Consolidation	0	0	0	0	603	603
Capital WIP	1,111	1,017	963	300	1,651	1,791
<b>Total Investments</b>	<b>71</b>	<b>3,381</b>	<b>5,418</b>	<b>5,983</b>	<b>5,360</b>	<b>9,045</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>3,939</b>	<b>3,762</b>	<b>3,952</b>	<b>6,671</b>	<b>6,013</b>	<b>5,095</b>
Inventory	1,571	1,749	2,011	2,834	3,128	2,312
Account Receivables	1,475	1,172	1,024	2,364	1,109	1,337
Cash and Bank Balance	129	141	97	473	680	505
Loans and Advances	764	701	821	1,000	1,095	942
<b>Curr. Liability &amp; Prov.</b>	<b>808</b>	<b>1,142</b>	<b>1,197</b>	<b>1,510</b>	<b>1,055</b>	<b>736</b>
Account Payables	575	855	928	1,074	787	462
Other Current Liabilities	156	127	177	269	142	122
Provisions	77	161	93	166	125	152
<b>Net Current Assets</b>	<b>3,131</b>	<b>2,620</b>	<b>2,755</b>	<b>5,161</b>	<b>4,958</b>	<b>4,359</b>
<b>Appl. of Funds</b>	<b>7,022</b>	<b>10,586</b>	<b>13,547</b>	<b>16,787</b>	<b>18,638</b>	<b>21,804</b>

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24
<b>EPS</b>	<b>42.9</b>	<b>123.8</b>	<b>141.9</b>	<b>163.8</b>	<b>161.6</b>	<b>118.5</b>
Cash EPS	47.4	133.1	154.4	179.2	180.4	140.0
BV/Share	231.8	331.8	463.8	599.8	681.5	805.4
DPS	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0
<b>Valuation (x)</b>						
P/E	10.8	3.7	3.3	2.8	2.9	3.9
Cash P/E	9.7	3.5	3.0	2.6	2.6	3.3
P/BV	2.0	1.4	1.0	0.8	0.7	0.6
EV/Sales	3.3	1.6	1.3	0.9	0.9	1.1
EV/EBITDA	7.3	3.5	3.0	2.1	2.1	2.9
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	-2.5	119.4	106.7	100.1	67.3	120.5
<b>Return Ratios (%)</b>						
RoE	37.0	43.9	35.7	30.8	25.2	15.9
RoCE	33.0	39.1	31.5	28.7	24.5	15.7
RoIC	38.8	47.9	48.5	39.6	36.9	24.4
<b>Working Capital Ratios</b>						
Fixed Asset Turnover (x)	1.1	1.8	1.8	1.9	1.6	1.2
Asset Turnover (x)	0.5	0.8	0.7	0.8	0.7	0.5
Inventory (Days)	152	77	73	78	85	80
Debtor (Days)	142	51	37	65	30	46
Creditor (Days)	56	37	34	30	21	16
<b>Leverage Ratio (x)</b>						
Current Ratio	4.9	3.3	3.3	4.4	5.7	6.9
Interest Cover Ratio	57.4	15.7	35.3	63.6	41.1	47.4
Net Debt/Equity	0.1	-0.2	-0.3	-0.4	-0.3	-0.4

### Consolidated - Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24
OP/(Loss) before Tax	1,579	4,045	4,677	6,676	5,597	4,057
Depreciation	115	237	312	383	465	518
Interest & Finance Charges	26	196	89	62	57	55
Direct Taxes Paid	-331	-864	-1,094	-1,843	-1,458	-1,100
(Inc)/Dec in WC	-883	542	-122	-1,940	58	474
<b>CF from Operations</b>	<b>506</b>	<b>4,156</b>	<b>3,862</b>	<b>3,338</b>	<b>4,719</b>	<b>4,005</b>
Others	-2	-86	-36	-38	-147	-420
<b>CF from Operating incl EO</b>	<b>504</b>	<b>4,069</b>	<b>3,825</b>	<b>3,300</b>	<b>4,572</b>	<b>3,585</b>
(Inc)/Dec in FA	-568	-1,029	-1,108	-752	-2,858	-518
<b>Free Cash Flow</b>	<b>-64</b>	<b>3,040</b>	<b>2,717</b>	<b>2,548</b>	<b>1,714</b>	<b>3,067</b>
(Pur)/Sale of Investments	-69	-3,248	-2,003	-2,924	780	-3,101
Others	2	166	22	2,342	161	28
<b>CF from Investments</b>	<b>-635</b>	<b>-4,111</b>	<b>-3,089</b>	<b>-1,334</b>	<b>-1,918</b>	<b>-3,590</b>
Issue of Shares	0	0	0	0	0	0
Inc/(Dec) in Debt	518	1,009	-415	-484	-268	-64
Interest Paid	-28	-172	-89	-62	-116	-75
Dividend Paid	-230	-767	-255	-1,018	-2,037	0
Others	0	3	3	0	-28	-32
<b>CF from Fin. Activity</b>	<b>260</b>	<b>73</b>	<b>-757</b>	<b>-1,565</b>	<b>-2,448</b>	<b>-170</b>
<b>Inc/Dec of Cash</b>	<b>129</b>	<b>32</b>	<b>-21</b>	<b>401</b>	<b>207</b>	<b>-175</b>
Opening Balance	0	109	117	72	473	680
<b>Closing Balance</b>	<b>129</b>	<b>141</b>	<b>96</b>	<b>473</b>	<b>680</b>	<b>505</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

**Specific Disclosures**

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:  
financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email ID: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CD/SL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.